Skip to main navigation
Madrigal Pharmaceuticals Madrigal Pharmaceuticals.
  • About Us
    • Overview
    • Leadership
    • Board Of Directors
  • Our Programs
    • Overview
    • Our Medicine
  • NASH
    • Overview
    • Resources
  • Investors & Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Financials and Filings
    • Stock Information
    • Corporate Governance
    • FAQs
    • Email Alerts
  • Careers
    • Join the team
    • Core Values
  • Contact
    • General Inquires
    • Medical Information Inquiries
    • Medical Education Grant Submissions
Search
  • About Us
    • Overview
    • Leadership
    • Board Of Directors
  • Our Programs
    • Overview
    • Our Medicine
  • NASH
    • Overview
    • Resources
  • Investors & Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Financials and Filings
    • Stock Information
    • Corporate Governance
    • FAQs
    • Email Alerts
  • Careers
    • Join the team
    • Core Values
  • Contact
    • General Inquires
    • Medical Information Inquiries
    • Medical Education Grant Submissions
  • Overview
  • Press Releases
  • Events and Presentations
  • Financials and Filings
  • Stock Information
  • Corporate Governance
  • FAQs
  • Email Alerts

Q1 2025 Earnings Call

May 1, 2025 at 8:00 AM EDT

Add to Outlook
Add to Google Calendar
Listen to webcast

Madrigal’s ambitious research programs led to the first FDA-approved treatment in NASH.

Learn More
Madrigal Pharmaceuticals. Logo

Madrigal Pharmaceuticals

200 Barr Harbor Drive,
Suite 200

West Conshohocken,
Pennsylvania 19428

  • About Us
  • Our Programs
  • NASH
  • Investors & Media
  • Careers
  • Contact
Madrigal Pharmaceuticals
  • Terms of Use
  • Privacy
  • Cookies
  • ETHICS and COMPLIANCE
  • TRANSPARENCY
©2025 Madrigal Pharmaceuticals. All rights reserved.